160 related articles for article (PubMed ID: 7655736)
1. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors.
Chemeris G; Loktinov A; Rempel A; Schwarz M; Bannasch P
Virchows Arch; 1995; 426(6):563-9. PubMed ID: 7655736
[TBL] [Abstract][Full Text] [Related]
2. A novel p53 mutation hotspot at codon 132 (AAG-->AGG) in human renal cancer.
Dahiya R; Deng G; Selph C; Carroll P; Presti J
Biochem Mol Biol Int; 1998 Feb; 44(2):407-15. PubMed ID: 9530523
[TBL] [Abstract][Full Text] [Related]
3. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour.
Contractor H; Zariwala M; Bugert P; Zeisler J; Kovacs G
J Pathol; 1997 Feb; 181(2):136-9. PubMed ID: 9120715
[TBL] [Abstract][Full Text] [Related]
4. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
5. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing.
Chakravarty G; Redkar A; Mittra I
Br J Cancer; 1996 Oct; 74(8):1181-7. PubMed ID: 8883402
[TBL] [Abstract][Full Text] [Related]
7. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations.
Coggi G; Bosari S; Roncalli M; Graziani D; Bossi P; Viale G; Buffa R; Ferrero S; Piazza M; Blandamura S; Segalin A; Bonavina L; Peracchia A
Cancer; 1997 Feb; 79(3):425-32. PubMed ID: 9028350
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the p53 gene in carcinomas of the urinary system.
Suzuki Y; Tamura G
Acta Pathol Jpn; 1993 Dec; 43(12):745-50. PubMed ID: 8109252
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas.
Oda H; Nakatsuru Y; Ishikawa T
Cancer Res; 1995 Feb; 55(3):658-62. PubMed ID: 7834636
[TBL] [Abstract][Full Text] [Related]
10. Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas.
Kikuchi Y; Kishi T; Suzuki M; Furusato M; Aizawa S
Virchows Arch; 1994; 424(3):229-33. PubMed ID: 8186888
[TBL] [Abstract][Full Text] [Related]
11. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
[TBL] [Abstract][Full Text] [Related]
12. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas.
Dix B; Robbins P; Carrello S; House A; Iacopetta B
Br J Cancer; 1994 Oct; 70(4):585-90. PubMed ID: 7917901
[TBL] [Abstract][Full Text] [Related]
13. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
14. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
[TBL] [Abstract][Full Text] [Related]
15. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Arndt H; Paeslack U; Werner M; Tan HK; Jonas U
Int J Cancer; 1995 Dec; 64(6):399-406. PubMed ID: 8550242
[TBL] [Abstract][Full Text] [Related]
16. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
17. p53 abnormalities are rare events in neuroendocrine (Merkel cell) carcinoma of the skin. An immunohistochemical and SSCP analysis.
Schmid M; Janssen K; Dockhorn-Dworniczak B; Metze D; Zelger BW; Luger TA; Schmid KW
Virchows Arch; 1997 Mar; 430(3):233-7. PubMed ID: 9099981
[TBL] [Abstract][Full Text] [Related]
18. The relation between p53 mutation and p53 immunostaining in non-melanoma skin cancer.
Campbell C; Quinn AG; Angus B; Rees JL
Br J Dermatol; 1993 Sep; 129(3):235-41. PubMed ID: 8286219
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
[TBL] [Abstract][Full Text] [Related]
20. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
